Syndax Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Syndax Pharmaceuticals
SNDX Stock  USD 21.14  0.57  2.63%   
Syndax Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Syndax Pharmaceuticals' valuation are provided below:
Gross Profit
-133.2 M
Profit Margin
(2.80)
Market Capitalization
1.9 B
Enterprise Value Revenue
12.886
Revenue
111.3 M
We have found one hundred twenty available fundamental trend indicators for Syndax Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Syndax Pharmaceuticals current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.4 B in 2026. Enterprise Value is likely to rise to about 1.2 B in 2026

Syndax Pharmaceuticals Total Revenue

29.85 Million

Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.8 K, Interest Expense of 6 M or Gross Profit of 15.6 M, as well as many indicators such as Price To Sales Ratio of 40.87, Dividend Yield of 0.0198 or PTB Ratio of 3.71. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Syndax Stock
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets875.2 M833.5 M283.4 M
Slightly volatile
Short and Long Term Debt Total417.5 M397.6 M76.3 M
Slightly volatile
Other Current Liabilities95.8 M91.2 M24.7 M
Slightly volatile
Total Current Liabilities125 M119.1 M35.6 M
Slightly volatile
Property Plant And Equipment Net2.4 M2.3 M780.2 K
Slightly volatile
Accounts Payable14 M13.4 M4.7 M
Slightly volatile
Cash186.1 M177.2 M81.9 M
Slightly volatile
Non Current Assets Total147 M140 M27.3 M
Slightly volatile
Non Currrent Assets Other185.5 K195.3 K664.3 K
Pretty Stable
Cash And Short Term Investments703.9 M670.3 M250.7 M
Slightly volatile
Common Stock Shares Outstanding73.2 M77.1 M73 B
Slightly volatile
Short Term Investments517.8 M493.2 M168.5 M
Slightly volatile
Liabilities And Stockholders Equity875.2 M833.5 M283.4 M
Slightly volatile
Non Current Liabilities Total402.3 M383.1 M75.6 M
Slightly volatile
Other Current Assets7.1 M6.8 M2.5 M
Slightly volatile
Total Liabilities527.3 M502.2 M111.2 M
Slightly volatile
Total Current Assets728.2 M693.5 M256.2 M
Slightly volatile
Short Term Debt11.9 M11.3 M7.6 M
Pretty Stable
Current Deferred Revenue47.1 M44.8 M14.4 M
Slightly volatile
Property Plant And Equipment Gross2.9 M2.8 M933.2 K
Slightly volatile
Common Stock Total Equity7.2 K6.9 K3.4 K
Slightly volatile
Common Stock10.9 K10.3 K4.2 K
Slightly volatile
Other Liabilities14.2 M13.4 M9.8 M
Slightly volatile
Long Term Debt400.4 M381.3 M113.1 M
Slightly volatile
Net Receivables16.7 M16 M3.2 M
Slightly volatile
Deferred Long Term Liabilities20.2 M19.3 M11.2 M
Slightly volatile
Short and Long Term Debt14.6 M13.9 M5.8 M
Slightly volatile
Preferred Stock Total Equity264.2 M375.3 M274.9 M
Slightly volatile
Property Plant Equipment1.3 M1.2 M487.9 K
Slightly volatile
Capital Surpluse669.6 M1.1 B624.1 M
Slightly volatile
Non Current Liabilities Other776.8 K817.6 K1.1 M
Pretty Stable
Net Invested Capital762.9 M726.6 M280.2 M
Slightly volatile
Net Working Capital332.7 M574.4 M244.1 M
Slightly volatile
Capital Stock6.3 K10.3 K4.3 K
Slightly volatile
Capital Lease Obligations1.3 M2.4 M1.1 M
Slightly volatile
Long Term Debt Total20.8 M22.9 M18.8 M
Slightly volatile

Syndax Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.8 K7.2 K42.3 K
Pretty Stable
Other Operating Expenses438.7 M417.9 M124.3 M
Slightly volatile
Research Development291.8 M277.9 M85.6 M
Slightly volatile
Total Operating Expenses437.8 M416.9 M124.1 M
Slightly volatile
Selling General Administrative146 M139 M38.5 M
Slightly volatile
Interest Income31.5 M30 M7.5 M
Slightly volatile
Reconciled Depreciation6.8 K7.2 K57.5 K
Slightly volatile

Syndax Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation6.8 K7.2 K42.3 K
Pretty Stable
Total Cash From Financing Activities426.7 M406.4 M138.4 M
Slightly volatile
End Period Cash Flow186.3 M177.4 M82 M
Slightly volatile
Stock Based Compensation52 M49.5 M14.4 M
Slightly volatile
Begin Period Cash Flow357 M340 M92.8 M
Slightly volatile
Sale Purchase Of Stock27.1 M28.6 M38.4 M
Pretty Stable
Change To Netincome8.2 M16.1 M7.2 M
Slightly volatile
Dividends Paid2.1 M2.3 M2.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio40.8743.02112
Very volatile
Dividend Yield0.01980.02230.0243
Slightly volatile
Days Sales Outstanding258246137
Slightly volatile
Stock Based Compensation To Revenue3.932.094.0691
Slightly volatile
Capex To Depreciation6.446.143.8873
Slightly volatile
EV To Sales47.7950.393.2935
Very volatile
Inventory Turnover1.812.032.2172
Slightly volatile
Days Of Inventory On Hand129146159
Slightly volatile
Payables Turnover0.05360.06390.0686
Pretty Stable
Sales General And Administrative To Revenue10.875.8711.6715
Slightly volatile
Research And Ddevelopement To Revenue11.1511.7417.3849
Pretty Stable
Capex To Revenue0.0010.00110.0502
Slightly volatile
Cash Per Share4.346.135.0795
Slightly volatile
Days Payables Outstanding6 K5.9 K5.3 K
Very volatile
Income Quality0.630.780.7812
Pretty Stable
Current Ratio7.025.247.9591
Slightly volatile
Receivables Turnover1.461.5422.6874
Pretty Stable
Capex Per Share0.0040.00330.0041
Very volatile
Revenue Per Share0.340.250.3003
Pretty Stable
Interest Debt Per Share3.873.690.9684
Slightly volatile
Debt To Assets0.520.551.5366
Slightly volatile
Graham Number7.358.279.0292
Slightly volatile
Operating Cycle355338177
Slightly volatile
Days Of Payables Outstanding6 K5.9 K5.3 K
Very volatile
Ebt Per Ebit1.181.081.0961
Slightly volatile
Effective Tax Rate0.00180.00140.0016
Slightly volatile
Quick Ratio7.05.247.9421
Slightly volatile
Net Income Per E B T0.80.90.981
Slightly volatile
Cash Ratio2.51.342.8115
Slightly volatile
Days Of Inventory Outstanding129146159
Slightly volatile
Days Of Sales Outstanding258246137
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0166
Slightly volatile
Fixed Asset Turnover15.110.5413.8611
Pretty Stable
Debt Ratio0.520.551.5366
Slightly volatile
Price Sales Ratio40.8743.02112
Very volatile
Asset Turnover0.04240.02940.0351
Slightly volatile
Gross Profit Margin0.780.870.9486
Slightly volatile

Syndax Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.4 B632.4 M
Slightly volatile
Enterprise Value1.2 B1.1 B529 M
Slightly volatile

Syndax Fundamental Market Drivers

Syndax Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44.8 M47.1 M
Cost Of Revenue743.4 K706.2 K
Total Revenue27.2 M29.8 M
Stock Based Compensation To Revenue 2.09  3.93 
Sales General And Administrative To Revenue 5.87  10.87 
Research And Ddevelopement To Revenue 11.74  11.15 
Revenue Per Share 0.25  0.34 
Ebit Per Revenue(12.91)(13.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY